Asunto(s)
Anticoncepción/métodos , Norgestrel/administración & dosificación , Adolescente , Adulto , Brasil , Chile , Ensayos Clínicos como Asunto , Anticonceptivos Orales Combinados/administración & dosificación , Anticonceptivos Orales Combinados/efectos adversos , República Dominicana , Implantes de Medicamentos , Femenino , Finlandia , Humanos , Jamaica , Levonorgestrel , Norgestrel/efectos adversos , Norgestrienona/administración & dosificación , Embarazo , Distribución AleatoriaAsunto(s)
Anticonceptivos , Norgestrel/farmacología , Adolescente , Adulto , Ensayos Clínicos como Asunto , Método Doble Ciego , Implantes de Medicamentos , Femenino , Humanos , Dispositivos Intrauterinos de Cobre/efectos adversos , Trastornos de la Menstruación/etiología , Norgestrel/efectos adversos , Norgestrienona/efectos adversos , Norgestrienona/farmacología , Embarazo , Países Escandinavos y Nórdicos , América del Sur , Indias OccidentalesRESUMEN
PIP: 990 women, 18-35 years of age, underwent subcutaneous silastic implants of levonorgestrel (N = 492) and norgestrionone (N = 498). These patients were compared to 402 women who used the Copper-T 200 IUD. Control examinations were performed 1,3,6,9, and 12 months after contraceptive use began. There were 3 pregnancies in the levo-norgestrel group which occurred during the first 4 months of contraceptive use. There were 17 pregnancies in the norgestrionone group, which occurred toward the end of the contraceptive use period. Menstrual bleeding disorders were the most frequent reasons for discontinuing subcutaneous implant use and occurred more often among the levo-norgestrel patients (generally metrorrhagia and menorrhagia). There were 4 pregnancies among the IUD patients. The continuation rate for the levo-norgestrel group was 74.6%; for the norgestrionone users 79.9%; and for the IUD users 81.1%. Anemia and changes in blood pressure were not observed among the subcutaneous implant patients. IUD patients showed no weight gain, while the subcutaneous implant patients gained on an average 1 kg.^ieng
Asunto(s)
Anticonceptivos Femeninos/administración & dosificación , Adolescente , Adulto , Ensayos Clínicos como Asunto , Anticonceptivos Femeninos/efectos adversos , Método Doble Ciego , Implantes de Medicamentos , Dismenorrea/inducido químicamente , Femenino , Humanos , Norgestrel/administración & dosificación , Norgestrienona/administración & dosificación , Países Escandinavos y Nórdicos , América del SurRESUMEN
PIP: An innocuous, sure, reversible means of male fertility control which does not disturb the libido is being sought. 20 healthy volunteers from ages 20 to 36 participated, using a 2nd form of protection when necessary. 10 received implants of 60 mg testosterone equally divided into 3 tubes, and began oral ingestion of 100 mg weekly, divided into daily doses, of R2323 (13-ethyl-17-hydroxy-gonen 4,9,11, trien-3-one) until the sperm became ineffective. Then oral doses were given according to personal requirements from 50 to 25 mg. The 2nd series of 10 received no testosterone implants, but followed the same scheme for oral ingestion. All patients but 1 reduced their sperm count and 80% were low enough to consider the sperm inactive. For those who used the hormone treatment as the only protection against pregnancy, no pregnancy occurred. Of the 1st group, 2 had excessive weight gain, 3 felt their libido reduced, and 1 had pain in the nipples and 1 had pain in the hepatic region. Recuperation of normal sperm characteristics was slow, especially motility and vitality. The spermogram is so altered during treatment that any accidental pregnancy could result in a defective egg and serious complications. It should definitely be avoided.^ieng